New Mounjaro KwikPen 2026
What has changed with the Mounjaro KwikPen?
The Mounjaro KwikPen device has been modified with several visual and structural updates. These updates are designed to improve how the pen indicates when the final dose has been delivered and when the pen should be discarded.
The modified device works in the same way as the original KwikPen.
How does the Mounjaro KwikPen work?
Both the original and modified Mounjaro KwikPens are:
- Disposable
- Multi-dose
- Single-patient-use
- Pre-filled injection pens
Each pen contains enough solution for:
- Priming before each injection
- Four fixed 0.6 mL doses
Patients administer one dose per week, meaning each pen typically lasts four weeks.
What changes have been made to the modified KwikPen?
The modified pen includes several design updates:
1. Plunger Position
The plunger sits further down in the cartridge when the pen is unused.
2. Extended Plunger
A new internal component has been added behind the plunger, extending its length. This is illustrated in the Mounjaro KwikPen Guide to Parts section of the Instructions For Use (IFU).
3. Clearer Indication When the Pen Is Empty
After the fourth dose, the plunger will be positioned near the end of the pen, clearly indicating that the pen has been used and is ready to be discarded.
When will the modified KwikPen be available in the UK?
The modified Mounjaro KwikPen is expected to become available in the UK from April 2026.
Supply will gradually transition to the modified pen once existing stock of the original device has been used.
Will both versions of the pen be available at the same time?
Yes.
During the transition period, both the original and modified KwikPens will be available.
Patients may receive either version when their prescription is dispensed. This will depend on:
- pharmacy stock
- distributor supply
- purchasing patterns across the country
The original KwikPen may continue to appear in supply until existing stock has been depleted.
Will the dosing or instructions change?
The modified KwikPen works in the same way as the original device, and there are no changes to dosing or weekly administration.
Patients should continue to follow the Instructions for Use provided with the pen.
How should adverse events or product complaints be reported?
Adverse events and product complaints should be reported through the MHRA Yellow Card Scheme.
Reports can be submitted online at:
Alternatively, search “MHRA Yellow Card” in the Google Play or Apple App Store.
Adverse events and product complaints should also be reported to Lilly UK:
Telephone: 01256 315 000